Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges

Cancer Letters

Volumn 305, Issue 2, 2011, Pages 123-143

  Bouchard, Michael J ^a   Navas Martin, Sonia ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocarcinogenesis; Hepatocellular carcinoma; Liver

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS B VIRUS X PROTEIN; MICRORNA; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; STRUCTURAL PROTEIN;

APOPTOSIS; CANCER INCIDENCE; CANCER RISK; CELL CYCLE PROGRESSION; CELL DESTRUCTION; CELL REGENERATION; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION; VIRUS CARCINOGENESIS; VIRUS CORE; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS REPLICATION;

HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 79955482701     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.11.014     Document Type: Review

References (214)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Wang X.W., Hussain S.P., Huo T., Wu C.G., Forgues M., Hofseth L.J., Brechot C., Harris C.C. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002, 181-182:43-47.
3. Guidotti L.G., Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 2006, 1:23-61.
4. Bartosch B., Thimme R., Blum H.E., Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J. Hepatol. 2009, 51:810-820.
5. Bouchard M.J., Schneider R.J. The enigmatic X gene of hepatitis B virus. J. Virol. 2004, 78:12725-12734.
6. Seeger C., Zoulim F., Mason W. Hepadnaviridae. Wolters Kluwer Health 2007, 2977-3030. Lippincott Williams & Wilkins, Philadelphia. D. Knipe, P. Howley (Eds.).
7. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 2005, 25:143-154.
8. Roberts L.R., Gores G.J. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin. Liver Dis. 2005, 25:212-225.
9. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J. Viral Hepat. 2004, 11:383-393.
10. Greenberger N. History taking and physical examination for the patient with liver diseases. Schiff's Diseases of the Liver 2007, 3-19. Lippincott Williams & Wilkins, Philadelphia. E.R. Schiff, M.F. Sorell, W.C. Maddrey (Eds.).
11. Beasley R., Lin C.-C., Hwang L.-Y., Chien C.-S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981, 1129-1133.
12. Hollinger F., Liang T. Hepatitis B Virus in Viral Hepatitis 2002, Lippincott Williams and Wilkins, Philadelphia, pp. 103-168.
13. Besisik F., Karaca C., Akyuz F., Horosanh S., Onel D., Badur S., Sever M., Danahoglu A., Demir K., Kaymakoglu S., Cakaloglu Y., Okten A. Occult HBV infection - both hidden and mysterious. Gastroenterology 2003, 125:1903-1905.
14. Guidotti L.G., Martinez V., Loh Y.T., Rogler C.E., Chisari F.V. Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice. J. Virol. 1994, 68:5469-5475.
15. Rabe B., Delaleau M., Bischof A., Foss M., Sominskaya I., Pumpens P., Cazenave C., Castroviejo M., Kann M. Nuclear entry of hepatitis B virus capsids involves disintegration to protein dimers followed by nuclear reassociation to capsids. PLoS Pathog. 2009, 5:e1000563.
16. Hartmann-Stuhler C., Prange R. Hepatitis B virus large envelope protein interacts with gamma2-adaptin, a clathrin adaptor-related protein. J. Virol. 2001, 75:5343-5351.
17. Kian Chua P., Lin M.H., Shih C. Potent inhibition of human hepatitis B virus replication by a host factor Vps4. Virology 2006, 354:1-6.
18. Rost M., Mann S., Lambert C., Doring T., Thome N., Prange R. Gamma-adaptin, a novel ubiquitin-interacting adaptor, and Nedd4 ubiquitin ligase control hepatitis B virus maturation. J. Biol. Chem. 2006, 281:29297-29308.
19. Watanabe T., Sorensen E.M., Naito A., Schott M., Kim S., Ahlquist P. Involvement of host cellular multivesicular body functions in hepatitis B virus budding. Proc. Natl. Acad. Sci. USA 2007, 104:10205-10210.
20. Guidotti L., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
21. Guidotti L.G. The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection. Vaccine 2002, 20(Suppl 4):A80-82.
22. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 2001, 19:65-91.
23. Prince A.M., Brotman B. Perspectives on hepatitis B studies with chimpanzees. ILAR J. 2001, 42:85-88.
24. Guidotti L., Matzke B., Schaller H., Chisari F. High-level hepatitis B virus replication in transgenic mice. J. Virol. 1995, 69:6158-6169.
25. Zheng Y., Chen W.L., Louie S.G., Yen T.S., Ou J.H. Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice. Hepatology 2007, 45:16-21.
26. Ando K., Guidotti L.G., Wirth S., Ishikawa T., Missale G., Moriyama T., Schreiber R.D., Schlicht H.J., Huang S.N., Chisari F.V. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J. Immunol. 1994, 152:3245-3253.
27. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:25-36.
28. Berasain C., Castillo J., Perugorria M.J., Latasa M.U., Prieto J., Avila M.A. Inflammation and liver cancer: new molecular links. Ann. NY Acad. Sci. 2009, 1155:206-221.
29. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
30. Bill C.A., Summers J. Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration. Proc. Natl. Acad. Sci. USA 2004, 101:11135-11140.
31. Bonilla Guerrero R., Roberts L.R. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J. Hepatol. 2005, 42:760-777.
32. Menne S., Cote P.J. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J. Gastroenterol. 2007, 13:104-124.
33. Wei Y., Fourel G., Ponzetto A., Silvestro M., Tiolais P., Buendia M.-A. Hepadnavirus integration: mechanisms of activation of the N-myc2 retrotransposon in woodchuck liver tumors. J. Virol. 1992, 5265-5276.
34. Ogston C.W., Jonak G.J., Rogler C.E., Astrin S.M., Summers J. Cloning and structural analysis of integrated woodchuck hepatitis virus sequences from hepatocellular carcinomas of woodchucks. Cell 1982, 29:385-394.
35. Moroy T., Marchio A., Etiemble J., Trepo C., Tiollais P., Buendia M.A. Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature 1986, 324:276-279.
36. Fourel G., Trepo C., Bougueleret L., Henglein B., Ponzetto A., Tiollais P., Buendia M.A. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 1990, 347:294-298.
37. Adhikary S., Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 2005, 6:635-645.
38. Feitelson M.A., Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 2007, 252:157-170.
39. Ferber M.J., Montoya D.P., Yu C., Aderca I., McGee A., Thorland E.C., Nagorney D.M., Gostout B.S., Burgart L.J., Boix L., Bruix J., McMahon B.J., Cheung T.H., Chung T.K., Wong Y.F., Smith D.I., Roberts L.R. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003, 22:3813-3820.
40. Ma N.F., Lau S.H., Hu L., Xie D., Wu J., Yang J., Wang Y., Wu M.C., Fung J., Bai X., Tzang C.H., Fu L., Yang M., Su Y.A., Guan X.Y. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin. Cancer Res. 2008, 14:5061-5068.
41. Wang Y., Lau S.H., Sham J.S., Wu M.C., Wang T., Guan X.Y. Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis. Oncogene 2004, 23:142-148.
42. Kekule A.S., Lauer U., Meyer M., Caselmann W.H., Hofschneider P.H., Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990, 343:457-461.
43. Chisari F., Pinkert C., Milich D., Filippi P., McLachlan A., Palmiter R., Brinster R. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985, 230:1157-1160.
44. Yen T.S. Hepadnaviral X protein: review of recent progress. J. Biomed. Sci. 1996, 3:20-30.
45. Murakami S., Cheong J., Kaneko S. Human hepatitis virus X gene encodes a regulatory domain that represses transactivation of X protein. J. Biol. Chem. 1994, 269:15118-15123.
46. Chen H., Kaneko S., Girones R., Anderson R., Hornbuckle W., Tennant B., Cote P., Gerin J., Purcell R., Miller R. The woodchuck helpatitis virus X gene is important for establishment of virus infection in woodchucks. J. Virol. 1993, 67:1218-1226.
47. Zoulim F., Saputelli J., Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J. Virol. 1994, 68:2026-2030.
48. Zhang Z., Torii N., Hu Z., Jacob J., Liang T. X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo. J. Clin. Invest. 2001, 108:1523-1531.
49. Xu Z., Yen T., Wu L., Madden C., Tan W., Slagle B., Ou J.-h. Enhancement of hepatitis B virus replication by its X protein in transgenic mice. J. Virol. 2002, 76:2579-2584.
50. Reifenberg K., Nusser P., Lohler J., Spindler G., Kuhn C., von Weizsacker F., Kock J. Virus replication and virion export in X-deficient hepatitis B virus transgenic mice. J. Gen. Virol. 2002, 83:991-996.
51. Keasler V.V., Hodgson A.J., Madden C.R., Slagle B.L. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J. Virol. 2007, 81:2656-2662.
52. Tateno C., Yoshizane Y., Saito N., Kataoka M., Utoh R., Yamasaki C., Tachibana A., Soeno Y., Asahina K., Hino H., Asahara T., Yokoi T., Furukawa T., Yoshizato K. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 2004, 165:901-912.
53. Tsuge M., Hiraga N., Akiyama R., Tanaka S., Matsushita M., Mitsui F., Abe H., Kitamura S., Hatakeyama T., Kimura T., Miki D., Mori N., Imamura M., Takahashi S., Hayes C.N., Chayama K. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. J. Gen. Virol. 2010, 91:1854-1864.
54. Tsuge M., Hiraga N., Takaishi H., Noguchi C., Oga H., Imamura M., Takahashi S., Iwao E., Fujimoto Y., Ochi H., Chayama K., Tateno C., Yoshizato K. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005, 42:1046-1054.
55. Leupin O., Bontron S., Schaeffer C., Strubin M. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. J. Virol. 2005, 79:4238-4245.
56. Sitterlin D., Bergametti F., Tiollais P., Tennant B.C., Transy C. Correct binding of viral X protein to UVDDB-p127 cellular protein is critical for efficient infection by hepatitis B viruses. Oncogene 2000, 19:4427-4431.
57. Zhang Z., Sun E., Ou J.H., Liang T.J. Inhibition of cellular proteasome activities mediates HBX-independent hepatitis B virus replication in vivo. J. Virol. 2010.
58. Zhang Z., Protzer U., Hu Z., Jacob J., Liang T.J. Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner. J. Virol. 2004, 78:4566-4572.
59. Balsano C., Billet O., Bennoun M., Cavard C., Zider A., Grimber G., Natoli G., Briand P., Levrero M. Hepatitis B virus X gene product acts as a transactivator in vivo. J. Hepat. 1994, 21:103-109.
60. Reifenberg K., Wilts H., Lohler J., Nusser P., Hanano R., Guidotti L.G., Chisari F.V., Schlicht H.J. The hepatitis B virus X protein transactivates viral core gene expression in vivo. J. Virol. 1999, 73:10399-10405.
61. Klein N., Bouchard M., Wang L.-H., Kobarg C., Schneider R. Src kinases involved in hepatitis B virus replication. EMBO J. 1999, 18:5019-5027.
62. Tarn C., Zou L., Hullinger R., Andrisani O. Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes. J. Virol. 2002, 76:9763-9772.
63. Bouchard M., Wang L.-H., Schneider R. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001, 294:2376-2378.
64. Bouchard M.J., Wang L.H., Schneider R.J. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001, 294:2376-2378.
65. Chami M., Ferrari D., Nicotera P., Paterlini-Brechot P., Rizzuto R. Caspase-dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X protein. J. Biol. Chem. 2003, 278:31745-31755.
66. Oh J.C., Jeong D.L., Kim I.K., Oh S.H. Activation of calcium signaling by hepatitis B virus-X protein in liver cells. Exp. Mol. Med. 2003, 35:301-309.
67. Clippinger A.J., Gearhart T.L., Bouchard M.J. Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-κB and the mitochondrial permeability transition pore. J. Virol. 2009, 83:4718-4731.
68. Gearhart T.L., Bouchard M.J. The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J. Virol. 2010.
69. Bouchard M.J., Puro R.J., Wang L., Schneider R.J. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J. Virol. 2003, 77:7713-7719.
70. McClain S.L., Clippinger A.J., Lizzano R., Bouchard M.J. HBV replication is associated with an HBx-dependent mitochondrial regulated increase in cytosolic calcium levels. J. Virol. 2007.
71. Rahmani Z., Huh K.-W., Lasher R., Siddiqui A. Hepatitis B virus X protein colocalizes to mitochondria with human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J. Virol. 2000, 74:2840-2846.
72. Clippinger A.J., Bouchard M.J. The hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J. Virol. 2008.
73. Pan J., Duan L.X., Sun B.S., Feitelson M.A. Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-kappa B. J. Gen. Virol. 2001, 82:171-182.
74. Elmore J., Hancock A., Chang S.-F., Wang X., Chang S., Callahan C., Geller D., Will H., Harris C. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc. Natl. Acad. Sci. USA 1997, 94:14707-14712.
75. Shih W.-L., Kuo M.-L., Chuang S.-E., Cheng A.-L., Doong S.-L. Hepatitis B virus X protein inhibits transforming growth factor-b-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J. Biol. Chem. 2000, 275:25858-25864.
76. Su F., Schneider R. Hepatits B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor a. Proc. Natl. Acad. Sci. USA 1997, 94:8744-8749.
77. Terradillos O., Pollicino T., Lecoeur H., Tripodi M., Gougeon M.L., Tiollais P., Buendia M.A. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998, 17:2115-2123.
78. Shintani Y., Yotsuyanagi H., Moriya K., Fujie H., Tsutsumi T., Kanegae Y., Kimura S., Saito I., Koike K. Induction of apoptosis after switch-on of the hepatitis B virus X gene mediated by the Cre/loxP recombination system. J. Gen. Virol. 1999, 80:3257-3265.
79. Shirakata Y., Koike K. Hepatitis B virus X protein induces cell death by causing loss of mitochondrial membrane potential. J. Biol. Chem. 2003, 278:22071-22078.
80. Takada S., Shirakata Y., Kaneniwa N., Koike K. Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death. Oncogene 1999, 18:6965-6973.
81. Kim S., Kim H.Y., Lee S., Kim S.W., Sohn S., Kim K., Cho H. Hepatitis B virus x protein induces perinuclear mitochondrial clustering in microtubule- and Dynein-dependent manners. J. Virol. 2007, 81:1714-1726.
82. Su F., Theodosis C., Schneider R. Role of NF-kB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J. Virol. 2001, 75:215-225.
83. Kim K.H., Seong B.L. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J. 2003, 22:2104-2116.
84. Karin M., Lawrence T., Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-835.
85. Madden C.R., Slagle B.L. Stimulation of cellular proliferation by hepatitis B virus X protein. Dis. Markers 2001, 17:153-157.
86. Bouchard M., Giannakopoulos S., Wang E.H., Tanese N., Schneider R.J. Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway. J. Virol. 2001, 75:4247-4257.
87. Lee S., Tarn C., Wang W.H., Chen S., Hullinger R.L., Andrisani O.M. Hepatitis B virus X protein differentially regulates cell cycle progression in X-transforming versus nontransforming hepatocyte (AML12) cell lines. J. Biol. Chem. 2002, 277:8730-8740.
88. Hodgson A.J., Keasler V.V., Slagle B.L. Premature cell cycle entry induced by hepatitis B virus regulatory HBx protein during compensatory liver regeneration. Cancer Res. 2008, 68:10341-10348.
89. Tralhao J., Roudier J., Morosan S., Giannini C., Tu H., Goulenok C., Carnot F., Zavala F., Joulin V., Kremsdorf D., Brechot C. Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver proliferation: an alternative mechanism of HBx-related pathogenesis. Proc. Natl. Acad. Sci. USA 2002, 99:6991-6996.
90. Wu B.K., Li C.C., Chen H.J., Chang J.L., Jeng K.S., Chou C.K., Hsu M.T., Tsai T.F. Blocking of G1/S transition and cell death in the regenerating liver of hepatitis B virus X protein transgenic mice. Biochem. Biophys. Res. Commun. 2006, 340:916-928.
91. Qiao L., Leach K., McKinstry R., Gilfor D., Yacoub A., Park J.-S., Grant S., Hylemon P., Fisher P., Dent P. Hepatitis B virus X protein increases expression of p21Cip-1/WAF1/MDA6 and p27Kip-1 in primary mouse hepatocytes, leading to a reduced cell cycle progression. Hepatology 2001, 34:906-917.
92. Gearhart T.L., Bouchard M.J. Replication of the hepatitis B virus requires a calcium-dependent HBx-induced G1 phase arrest of hepatocytes. Virology 2010, 407:14-25.
93. Cohen D., Adamovich Y., Reuven N., Shaul Y. Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. Hepatology 2010, 51:1538-1546.
94. Koike K. Hepatitis B virus X gene is implicated in liver carcinogenesis. Cancer Lett. 2009, 286:60-68.
95. Kim C., Koike K., Saito I., Miyamura T., Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 353:317-320.
96. Yu D.Y., Moon H.B., Son J.K., Jeong S., Yu S.L., Yoon H., Han Y.M., Lee C.S., Park J.S., Lee C.H., Hyun B.H., Murakami S., Lee K.K. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J. Hepatol. 1999, 31:123-132.
97. Slagle B.L., Lee T.H., Medina D., Finegold M.J., Butel J.S. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol. Carcinogen. 1996, 15:261-269.
98. Terradillos O., Billet O., Renard C.A., Lévy L.R., Molina T., Briand P., Buendia M.-A. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997, 14:395-404.
99. Madden C., Finegold M., Slagle B. Hepatitis B virus X protein acts a a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J. Virol. 2001, 75:3851-3858.
100. Becker S., Lee T.-H., Butel J., Slagle B. Hepatitis B virus X protein interferes with cellular DNA repair. J. Virol. 1998, 72:266-272.
101. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
102. Recommendations from the National Institutes of Health consensus development conference statement: management of hepatitis C: 2002. Hepatology 36 (2002) 1039.
103. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral. Hepat. 2006, 13:34-41.
104. Alter M.J. Epidemiology of hepatitis C in the West. Semin. Liver Dis. 1995, 15:5-14.
105. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., Watanabe Y., Koi S., Onji M., Ohta Y., et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 1990, 87:6547-6549.
106. Chisari F.V. Unscrambling hepatitis C virus-host interactions. Nature 2005, 436:930-932.
107. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
108. Blanchard E., Belouzard S., Goueslain L., Wakita T., Dubuisson J., Wychowski C., Rouille Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2006, 80:6964-6972.
109. Helle F., Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol. Life Sci. 2008, 65:100-112.
110. Suzuki T., Aizaki H., Murakami K., Shoji I., Wakita T. Molecular biology of hepatitis C virus. J. Gastroenterol. 2007, 42:411-423.
111. Deleersnyder V., Pillez A., Wychowski C., Blight K., Xu J., Hahn Y.S., Rice C.M., Dubuisson J. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 1997, 71:697-704.
112. Brohm C., Steinmann E., Friesland M., Lorenz I.C., Patel A., Penin F., Bartenschlager R., Pietschmann T. Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. J. Virol. 2009, 83:11682-11693.
113. Yi M., Ma Y., Yates J., Lemon S.M. Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. PLoS Pathog. 2009, 5:e1000403.
114. Beran R.K., Lindenbach B.D., Pyle A.M. The NS4A protein of hepatitis C virus promotes RNA-coupled ATP hydrolysis by the NS3 helicase. J. Virol. 2009, 83:3268-3275.
115. Foy E., Li K., Wang C., Sumpter R., Ikeda M., Lemon S.M., Gale M. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148.
116. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
117. Behrens S.E., Tomei L., De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 1996, 15:12-22.
118. Timm J., Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J. Gastroenterol. 2007, 13:4808-4817.
119. Lawson A. Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease?. J. Viral. Hepat. 2010, 17:51-58.
120. Pradat P., Voirin N., Tillmann H.L., Chevallier M., Trepo C. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int. 2007, 27:335-339.
121. Kumar D., Farrell G.C., Kench J., George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J. Gastroenterol. Hepatol. 2005, 20:1395-1400.
122. Morgan T.R., Mandayam S., Jamal M.M. Alcohol and hepatocellular carcinoma. Gastroenterology 2004, 127:S87-96.
123. Williams M.J., Lang-Lenton M. Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J. Viral. Hepat. 2010.
124. Potthoff A., Manns M.P., Wedemeyer H. Treatment of HBV/HCV coinfection. Expert Opin. Pharmacother. 2010, 11:919-928.
125. Clifford G.M., Rickenbach M., Polesel J., Dal Maso L., Steffen I., Ledergerber B., Rauch A., Probst-Hensch N.M., Bouchardy C., Levi F., Franceschi S. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008, 22:2135-2141.
126. Bengsch B., Thimme R., Blum H.E. Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses 2009, 1:104-105.
127. McGivern D.R., Lemon S.M. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu. Rev. Pathol. 2009, 4:399-415.
128. Fujita N., Sugimoto R., Ma N., Tanaka H., Iwasa M., Kobayashi Y., Kawanishi S., Watanabe S., Kaito M., Takei Y. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J. Viral. Hepat. 2008, 15:498-507.
129. Joyce M.A., Walters K.A., Lamb S.E., Yeh M.M., Zhu L.F., Kneteman N., Doyle J.S., Katze M.G., Tyrrell D.L. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathog. 2009, 5:e1000291.
130. Swietek K., Juszczyk J. Reduced glutathione concentration in erythrocytes of patients with acute and chronic viral hepatitis. J. Viral. Hepat. 1997, 4:139-141.
131. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., Matsuura Y., Kimura S., Miyamura T., Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 1998, 4:1065-1067.
132. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., Lemon S.M., Weinman S.A. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-375.
133. Robinson L.C., Marchant J.S. Enhanced Ca2+ leak from ER Ca2+ stores induced by hepatitis C NS5A protein. Biochem. Biophys. Res. Commun. 2008, 368:593-599.
134. Park C.Y., Choi S.H., Kang S.M., Kang J.I., Ahn B.Y., Kim H., Jung G., Choi K.Y., Hwang S.B. Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J. Hepatol. 2009, 51:853-864.
135. Milward A., Mankouri J., Harris M. Hepatitis C virus NS5A protein interacts with beta-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion. J. Gen. Virol. 2010, 91:373-381.
136. Tsai W.L., Chung R.T. Viral hepatocarcinogenesis. Oncogene 2010, 29:2309-2324.
137. Lonardo A., Adinolfi L.E., Loria P., Carulli N., Ruggiero G., Day C.P. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004, 126:586-597.
138. Nishida N., Nagasaka T., Nishimura T., Ikai I., Boland C.R., Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008, 47:908-918.
139. Kew M.C. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett. 2009, 286:38-43.
140. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
141. Fujita N., Sugimoto R., Motonishi S., Tomosugi N., Tanaka H., Takeo M., Iwasa M., Kobayashi Y., Hayashi H., Kaito M., Takei Y. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J. Hepatol. 2008, 49:702-710.
142. Bureau C., Bernad J., Chaouche N., Orfila C., Beraud M., Gonindard C., Alric L., Vinel J.P., Pipy B. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J. Biol. Chem. 2001, 276:23077-23083.
143. Gong G., Waris G., Tanveer R., Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc. Natl. Acad. Sci. USA 2001, 98:9599-9604.
144. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., Younossi Z., Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75-85.
145. Leandro G., Mangia A., Hui J., Fabris P., Rubbia-Brandt L., Colloredo G., Adinolfi L.E., Asselah T., Jonsson J.R., Smedile A., Terrault N., Pazienza V., Giordani M.T., Giostra E., Sonzogni A., Ruggiero G., Marcellin P., Powell E.E., George J., Negro F. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006, 130:1636-1642.
146. Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., Ishibashi K., Matsuura Y., Miyamura T., Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 1997, 78(Pt 7):1527-1531.
147. Mirandola S., Bowman D., Hussain M.M., Alberti A. Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). Nutr. Metab. (Lond.) 2010, 7:13.
148. Park C.Y., Jun H.J., Wakita T., Cheong J.H., Hwang S.B. Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J. Biol. Chem. 2009, 284:9237-9246.
149. Dharancy S., Malapel M., Perlemuter G., Roskams T., Cheng Y., Dubuquoy L., Podevin P., Conti F., Canva V., Philippe D., Gambiez L., Mathurin P., Paris J.C., Schoonjans K., Calmus Y., Pol S., Auwerx J., Desreumaux P. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005, 128:334-342.
150. Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Tsukamoto K., Kimura S., Moriya K., Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-848.
151. Koike K. Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH. Hepatol. Res. 2005, 33:145-150.
152. Munakata T., Liang Y., Kim S., McGivern D.R., Huibregtse J., Nomoto A., Lemon S.M. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog. 2007, 3:1335-1347.
153. McGivern D.R., Villanueva R.A., Chinnaswamy S., Kao C.C., Lemon S.M. Impaired replication of hepatitis C virus containing mutations in a conserved NS5B retinoblastoma protein-binding motif. J. Virol. 2009, 83:7422-7433.
154. Madhoun M.F., Fazili J., Bright B.C., Bader T., Roberts D.N., Bronze M.S. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am. J. Med. Sci. 2010, 339:169-173.
155. Wang A.G., Lee D.S., Moon H.B., Kim J.M., Cho K.H., Choi S.H., Ha H.L., Han Y.H., Kim D.G., Hwang S.B., Yu D.Y. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J. Pathol. 2009, 219:253-262.
156. Majumder M., Steele R., Ghosh A.K., Zhou X.Y., Thornburg L., Ray R., Phillips N.J., Ray R.B. Expression of hepatitis C virus non-structural 5A protein in the liver of transgenic mice. FEBS Lett. 2003, 555:528-532.
157. Thomson M., Nascimbeni M., Havert M.B., Major M., Gonzales S., Alter H., Feinstone S.M., Murthy K.K., Rehermann B., Liang T.J. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J. Virol. 2003, 77:862-870.
158. Branch A.D., Stump D.D., Gutierrez J.A., Eng F., Walewski J.L. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin. Liver Dis. 2005, 25:105-117.
159. Lerat H., Honda M., Beard M.R., Loesch K., Sun J., Yang Y., Okuda M., Gosert R., Xiao S.Y., Weinman S.A., Lemon S.M. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122:352-365.
160. Roingeard P., Hourioux C. Hepatitis C virus core protein, lipid droplets and steatosis. J. Viral. Hepat. 2008, 15:157-164.
161. Ray R.B., Steele R. Separate domains of MBP-1 involved in c-myc promoter binding and growth suppressive activity. Gene 1997, 186:175-180.
162. Alisi A., Giambartolomei S., Cupelli F., Merlo P., Fontemaggi G., Spaziani A., Balsano C. Physical and functional interaction between HCV core protein and the different p73 isoforms. Oncogene 2003, 22:2573-2580.
163. Cho J., Baek W., Yang S., Chang J., Sung Y.C., Suh M. HCV core protein modulates Rb pathway through pRb down-regulation and E2F-1 up-regulation. Biochim. Biophys. Acta 2001, 1538:59-66.
164. Uchida M., Hino N., Yamanaka T., Fukushima H., Imanishi T., Uchiyama Y., Kodama T., Doi T. Hepatitis C virus core protein binds to a C-terminal region of NS5B RNA polymerase. Hepatol. Res. 2002, 22:297-306.
165. Joo M., Hahn Y.S., Kwon M., Sadikot R.T., Blackwell T.S., Christman J.W. Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta. J. Virol. 2005, 79:7648-7657.
166. Tai D.I., Tsai S.L., Chang Y.H., Huang S.N., Chen T.C., Chang K.S., Liaw Y.F. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 2000, 89:2274-2281.
167. Hayashi J., Aoki H., Kajino K., Moriyama M., Arakawa Y., Hino O. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor a. Hepatology 2000, 32:958-961.
168. Fukutomi T., Zhou Y., Kawai S., Eguchi H., Wands J.R., Li J. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology 2005, 41:1096-1105.
169. Shin J.Y., Hur W., Wang J.S., Jang J.W., Kim C.W., Bae S.H., Jang S.K., Yang S.H., Sung Y.C., Kwon O.J., Yoon S.K. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp. Mol. Med. 2005, 37:138-145.
170. Neuman M.G., Benhamou J.P., Bourliere M., Ibrahim A., Malkiewicz I., Asselah T., Martinot-Peignoux M., Shear N.H., Katz G.G., Akremi R., Benali S., Boyer N., Lecomte L., Le Breton V., Le Guludec G., Marcellin P. Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine 2002, 17:108-117.
171. Pavio N., Battaglia S., Boucreux D., Arnulf B., Sobesky R., Hermine O., Brechot C. Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway. Oncogene 2005, 24:6119-6132.
172. Taniguchi H., Kato N., Otsuka M., Goto T., Yoshida H., Shiratori Y., Omata M. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J. Med. Virol. 2004, 72:52-59.
173. Bataller R., Paik Y.H., Lindquist J.N., Lemasters J.J., Brenner D.A. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004, 126:529-540.
174. Bach N., Thung S.N., Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992, 15:572-577.
175. Tsutsumi T., Suzuki T., Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., Matsuura Y., Kimura S., Koike K., Miyamura T. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 2002, 304:415-424.
176. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-110.
177. Pavio N., Romano P.R., Graczyk T.M., Feinstone S.M., Taylor D.R. Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2alpha kinase PERK. J. Virol. 2003, 77:3578-3585.
178. Zhao L.J., Wang L., Ren H., Cao J., Li L., Ke J.S., Qi Z.T. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp. Cell Res. 2005, 305:23-32.
179. Koike K., Moriya K., Ishibashi K., Matsuura Y., Suzuki T., Saito I., Iino S., Kurokawa K., Miyamura T. Expression of hepatitis C virus envelope proteins in transgenic mice. J. Gen. Virol. 1995, 76(Pt 12):3031-3038.
180. Dustin L.B., Rice C.M. Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 2007, 25:71-99.
181. Dumoulin F.L., von dem Bussche A., Li J., Khamzina L., Wands J.R., Sauerbruch T., Spengler U. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology 2003, 305:260-266.
182. Erdtmann L., Franck N., Lerat H., Le Seyec J., Gilot D., Cannie I., Gripon P., Hibner U., Guguen-Guillouzo C. The hepatitis C virus NS2 protein is an inhibitor of CIDE-B-induced apoptosis. J. Biol. Chem. 2003, 278:18256-18264.
183. Smirnova I.S., Aksenov N.D., Vonsky M.S., Isaguliants M.G. Different transformation pathways of murine fibroblast NIH 3T3 cells by hepatitis C virus core and NS3 proteins. Cell Biol. Int. 2006, 30:915-919.
184. Zemel R., Gerechet S., Greif H., Bachmatove L., Birk Y., Golan-Goldhirsh A., Kunin M., Berdichevsky Y., Benhar I., Tur-Kaspa R. Cell transformation induced by hepatitis C virus NS3 serine protease. J. Viral. Hepat. 2001, 8:96-102.
185. Kwun H.J., Jung E.Y., Ahn J.Y., Lee M.N., Jang K.L. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J. Gen. Virol. 2001, 82:2235-2241.
186. Saito T., Owen D.M., Jiang F., Marcotrigiano J., Gale M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008, 454:523-527.
187. Gouttenoire J., Penin F., Moradpour D. Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. Rev. Med. Virol. 2010, 20:117-129.
188. Wang A.G., Moon H.B., Kim J.M., Hwang S.B., Yu D.Y., Lee D.S. Expression of hepatitis C virus nonstructural 4B in transgenic mice. Exp. Mol. Med. 2006, 38:241-246.
189. Park J.S., Yang J.M., Min M.K. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem. Biophys. Res. Commun. 2000, 267:581-587.
190. Einav S., Sklan E.H., Moon H.M., Gehrig E., Liu P., Hao Y., Lowe A.W., Glenn J.S. The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection. Hepatology 2008, 47:827-835.
191. Gimenez-Barcons M., Wang C., Chen M., Sanchez-Tapias J.M., Saiz J.C., Gale M. The oncogenic potential of hepatitis C virus NS5A sequence variants is associated with PKR regulation. J. Interf. Cytok. Res. 2005, 25:152-164.
192. Chung Y.L., Sheu M.L., Yen S.H. Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int. J. Cancer 2003, 107:65-73.
193. Mankouri J., Dallas M.L., Hughes M.E., Griffin S.D., Macdonald A., Peers C., Harris M. Suppression of a pro-apoptotic K+ channel as a mechanism for hepatitis C virus persistence. Proc. Natl. Acad. Sci. USA 2009, 106:15903-15908.
194. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
195. Taganov K.D., Boldin M.P., Baltimore D. MicroRNAs and immunity: tiny players in a big field. Immunity 2007, 26:133-137.
196. Wang W.X., Wilfred B.R., Baldwin D.A., Isett R.B., Ren N., Stromberg A., Nelson P.T. Focus on RNA isolation: obtaining RNA for microRNA (miRNA) expression profiling analyses of neural tissue. Biochim. Biophys. Acta 2008, 1779:749-757.
197. Jiang J., Gusev Y., Aderca I., Mettler T.A., Nagorney D.M., Brackett D.J., Roberts L.R., Schmittgen T.D. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 2008, 14:419-427.
198. Wong Q.W., Lung R.W., Law P.T., Lai P.B., Chan K.Y., To K.F., Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008, 135:257-269.
199. Fornari F., Gramantieri L., Giovannini C., Veronese A., Ferracin M., Sabbioni S., Calin G.A., Grazi G.L., Croce C.M., Tavolari S., Chieco P., Negrini M., Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009, 69:5761-5767.
200. Murakami Y., Yasuda T., Saigo K., Urashima T., Toyoda H., Okanoue T., Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25:2537-2545.
201. Ura S., Honda M., Yamashita T., Ueda T., Takatori H., Nishino R., Sunakozaka H., Sakai Y., Horimoto K., Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009, 49:1098-1112.
202. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
203. Henke J.I., Goergen D., Zheng J., Song Y., Schuttler C.G., Fehr C., Junemann C., Niepmann M. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008, 27:3300-3310.
204. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., Kauppinen S., Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
205. Kutay H., Bai S., Datta J., Motiwala T., Pogribny I., Frankel W., Jacob S.T., Ghoshal K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell Biochem. 2006, 99:671-678.
206. Gramantieri L., Ferracin M., Fornari F., Veronese A., Sabbioni S., Liu C.G., Calin G.A., Giovannini C., Ferrazzi E., Grazi G.L., Croce C.M., Bolondi L., Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007, 67:6092-6099.
207. Varnholt H., Drebber U., Schulze F., Wedemeyer I., Schirmacher P., Dienes H.P., Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008, 47:1223-1232.
208. Wang Y., Kato N., Jazag A., Dharel N., Otsuka M., Taniguchi H., Kawabe T., Omata M. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology 2006, 130:883-892.
209. Lipardi C., Wei Q., Paterson B.M. RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell 2001, 107:297-307.
210. Wang Y., Lu Y., Toh S.T., Sung W.K., Tan P., Chow P., Chung A.Y., Jooi L.L., Lee C.G. Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J. Hepatol. 2010, 53:57-66.
211. Yang L., Ma Z., Wang D., Zhao W., Chen L., Wang G. MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biol. Ther. 2010, 9.
212. Huang J., Wang Y., Guo Y., Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010, 52:60-70.
213. Qiu L., Fan H., Jin W., Zhao B., Wang Y., Ju Y., Chen L., Chen Y., Duan Z., Meng S. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem. Biophys. Res. Commun. 2010, 398:771-777.
214. Bressac B., Galvin K., Liang T., Isselbacher K., Wands J., Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 1990, 87:1973-1977.